#United States #Palatin Technologies #Cranbury #tirzepatide #Bremelanotide

Promising Results from Palatin Technologies' Phase 2 Obesity Study

Palatin Technologies, Inc., a trailblazer in biopharmaceutical developments, has recently unveiled positive outcomes from its Phase 2 obesity study, shedding light on the efficacy of its melanocortin-4 receptor (MC4R) agonist, bremelanotide, in combination with tirzepatide. This groundbreaking research highlights the potential of these compounds not only in appetite suppression but also in long-term weight maintenance.

The study, classified under BMT-801, assessed various treatment arms, including those with a combination of bremelanotide and tirzepatide, each administered alone, and their impacts on appetite and fullness. The results demonstrated that participants taking both medications experienced significant enhancements in appetite suppression, a crucial factor in successful weight management.

Carl Spana, Ph.D., President and CEO of Palatin, expressed enthusiasm regarding the findings, stating, "We're excited with the results, which demonstrated that low-dose bremelanotide matched tirzepatide in appetite suppression, a compelling outcome." He further emphasized the importance of the study's findings, particularly noting the reduction in appetite rebound—a common challenge faced after discontinuation of GLP-1/GIP therapies.

Key Findings

The results collected from a validated daily appetite questionnaire highlighted notable improvements across multiple parameters:

• - Overall Appetite Suppression: Bremelanotide plus tirzepatide showed a 71% increase, aligning closely with tirzepatide alone at 73% and bremelanotide alone at 71%.
• - Fullness: An increase of 65% was noted in participants taking both treatments, compared to 62% for tirzepatide alone and 79% for bremelanotide alone.
• - Satiety: There was a 56% increase in satiety among those on the combination treatment, on par with tirzepatide and surpassing bremelanotide alone.

Furthermore, while standard GLP-1/GIP treatments often lead to rapid weight regain upon cessation—over 50% within two weeks—this study revealed that transitioning patients to low-dose bremelanotide post-tirzepatide resulted in sustained weight maintenance with minimal regression.

Future Directions

The topline results from the ongoing BMT-801 Phase 2 trial also disclosed that participants receiving the combination treatment lost statistically significant weight over an 8-week period compared to placebo groups. As the trial continues, a detailed analysis of secondary outcomes such as body composition and BMI is in progress, with comprehensive results expected to be submitted for presentation at an upcoming medical conference.

Palatin Technologies is proactively developing further advancements in its MC4R agonist portfolio, focusing on next-generation compounds that include long-acting peptides and oral formulations aimed at various obesity applications. Their innovative approach seeks to address both common obesity challenges and complex genetic disorders associated with appetite regulation.

These advancements are slated for Investigational New Drug (IND) submissions by the end of Q4 2025, with initial clinical findings anticipated in the first half of 2026. As impatience grows regarding obesity management solutions, Palatin's commitment to exploring the potential of MC4R agonists might offer a beacon of hope for those struggling with weight management.

Conclusion

The promising results from Palatin Technologies' Phase 2 study signal a crucial step forward in obesity treatment options, emphasizing the role of MC4R agonists in fostering both appetite control and long-term weight maintenance. As research progresses, the future holds the potential for improved healthcare outcomes in obesity management, an essential public health issue facing many today.